Cancer Rop Co. Ltd. Cash Flow Conversion Efficiency
Cancer Rop Co. Ltd. cash flow conversion efficiency. Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-10.04 Billion ≈ $-6.81 Million USD) by net assets (₩90.79 Billion ≈ $61.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 180400 market cap for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Cancer Rop Co. Ltd. (2014–2025)
Cash flow conversion efficiency of Cancer Rop Co. Ltd. from 2014 to 2025. This chart illustrates how Cancer Rop Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Cancer Rop Co. Ltd. stock price today for real-time trading data and today's change.
Cancer Rop Co. Ltd. Cash Flow Conversion Ratio Explained
Cancer Rop Co. Ltd. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cancer Rop Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cancer Rop Co. Ltd. ranked by their cash flow conversion efficiency. Review Cancer Rop Co. Ltd. (180400) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STLLR Gold Inc.
TO:STLR
|
-0.045x |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
0.030x |
|
Thai Steel Cable Public Company Limited
BK:TSC
|
0.023x |
|
Severn Trent PLC
LSE:SVT
|
0.224x |
|
Atlas Salt Inc
V:SALT
|
-0.063x |
|
RumbleON Inc
NASDAQ:RMBL
|
-2.319x |
|
John Hancock Income Securities Closed Fund
NYSE:JHS
|
0.026x |
|
Joyce Corporation Ltd
AU:JYC
|
0.524x |
Annual Cash Flow Conversion Efficiency for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cancer Rop Co. Ltd. from 2014 to 2025. Also see Cancer Rop Co. Ltd. assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.76 Billion ≈ $64.90 Million |
₩-18.85 Billion ≈ $-12.78 Million |
-0.197x | +83.92% |
| 2024-12-31 | ₩16.35 Billion ≈ $11.08 Million |
₩-20.03 Billion ≈ $-13.57 Million |
-1.224x | -192.35% |
| 2023-12-31 | ₩28.80 Billion ≈ $19.51 Million |
₩-12.06 Billion ≈ $-8.17 Million |
-0.419x | -1762.27% |
| 2022-12-31 | ₩34.35 Billion ≈ $23.28 Million |
₩865.55 Million ≈ $586.57K |
0.025x | +117.79% |
| 2018-12-31 | ₩34.91 Billion ≈ $23.65 Million |
₩-4.94 Billion ≈ $-3.35 Million |
-0.142x | -130.41% |
| 2017-12-31 | ₩34.75 Billion ≈ $23.55 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.061x | -18.79% |
| 2016-12-31 | ₩29.05 Billion ≈ $19.69 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.052x | -32.60% |
| 2015-12-31 | ₩21.56 Billion ≈ $14.61 Million |
₩-841.17 Million ≈ $-570.05K |
-0.039x | -135.75% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
₩783.83 Million ≈ $531.19K |
0.109x | -- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more